Drugs / ACI-24.060
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05462106 | Jun 2022 → Apr 2029 expected | Alzheimer disease, amyloidosis | AC Immune SA | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-12-10 | AC Immune SA | Results AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome acimmune.com ↗
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim safety and tolerability data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals living with Down syndrome (DS). |
| 2024-02-22 | AC Immune SA | Results AC Immune Announces Upcoming Presentations at AD/PD™ 2024 acimmune.com ↗
Anti-Abeta liposomal vaccine, ACI-24.060, retains memory in aggressive mouse model of Alzheimer's disease |
| 2023-06-27 | AC Immune SA | Regulatory AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease acimmune.com ↗
today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease. |
| 2023-01-26 | AC Immune SA | Results AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial acimmune.com ↗
ACI-24.060 was generally well tolerated with no safety concerns observed |
All press releases naming this drug 4 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACI-24.060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05462106 ↗ |